{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T22:28:59Z","timestamp":1787178539169,"version":"build-2736575974"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Retinopathy of prematurity (ROP) is the leading cause of preventable childhood blindness worldwide. Although interventions such as anti-VEGF and laser have high success rates in treating severe ROP, current treatment and preventative strategies still have their limitations. Thus, we aim to identify drugs and chemicals for ROP with comprehensive safety profiles and tolerability using a computational bioinformatics approach.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We generated a list of genes associated with ROP to date by querying PubMed Gene which draws from animal models, human studies, and genomic studies in the NCBI database. Gene enrichment analysis was performed on the ROP gene list with the ToppGene program which draws from multiple drug-gene interaction databases to predict compounds with significant associations to the ROP gene list. Compounds with significant toxicities or without known clinical indications were filtered out from the final drug list.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The NCBI query identified 47 ROP genes with pharmacologic annotations present in ToppGene. Enrichment analysis revealed multiple drugs and chemical compounds related to the ROP gene list. The top ten most significant compounds associated with ROP include ascorbic acid, simvastatin, acetylcysteine, niacin, castor oil, penicillamine, curcumin, losartan, capsaicin, and metformin. Antioxidants, NSAIDs, antihypertensives, and anti-diabetics are the most common top drug classes derived from this analysis, and many of these compounds have potential to be readily repurposed for ROP as new prevention and treatment strategies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This bioinformatics analysis creates an unbiased approach for drug discovery by identifying compounds associated to the known genes and pathways of ROP. While predictions from bioinformatic studies require preclinical\/clinical studies to validate their results, this technique could certainly guide future investigations for pathologies like ROP.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2023.1151239","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T07:12:20Z","timestamp":1688973140000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Identifying novel candidate compounds for therapeutic strategies in retinopathy of prematurity via computational drug-gene association analysis"],"prefix":"10.3389","volume":"11","author":[{"given":"Edward F.","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hilkert Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingqing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonnah","family":"Reem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinanath","family":"Sulakhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Skondra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.5409\/wjcp.v5.i1.35","article-title":"Retinopathy of prematurity: past, present and future","volume":"5","author":"Shah","year":"2016","journal-title":"World J Clin Pediatr"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e2021053924","DOI":"10.1542\/peds.2021-053924","article-title":"Retinopathy of prematurity: a global perspective and recent developments","volume":"150","author":"Sabri","year":"2022","journal-title":"Pediatrics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.survophthal.2016.12.004","article-title":"Advances in understanding and management of retinopathy of prematurity","volume":"62","author":"Hartnett","year":"2017","journal-title":"Surv Ophthalmol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10456-007-9066-0","article-title":"Retinopathy of prematurity","volume":"10","author":"Chen","year":"2007","journal-title":"Angiogenesis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"S0161-6420(23)00245-2","DOI":"10.1016\/j.ophtha.2023.04.004","article-title":"Causes of childhood blindness in the United States using the IRIS\u00ae registry (intelligent research in sight)","author":"Lim","year":"2023","journal-title":"Ophthalmology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/pr.2013.205","article-title":"Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010","volume":"74","author":"Blencowe","year":"2013","journal-title":"Pediatr Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/s0022-3476(97)70031-3","article-title":"Vitamin E prophylaxis to reduce retinopathy of prematurity: a reappraisal of published trials","volume":"131","author":"Raju","year":"1997","journal-title":"J Pediatr"},{"key":"B8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41433-021-01465-6","article-title":"Evaluation of pro-oxidant antioxidant balance in retinopathy of prematurity","volume":"36","author":"Boskabadi","year":"2022","journal-title":"Eye (Lond)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1001\/jama.2018.5725","article-title":"Association between oxygen saturation targeting and death or disability in extremely preterm infants in the neonatal oxygenation prospective meta-analysis collaboration","volume":"319","author":"Askie","year":"2018","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1001\/jamaophthalmol.2018.7021","article-title":"Comparison of biphasic vs. static oxygen saturation targets among infants with retinopathy of prematurity","volume":"137","author":"Shukla","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1136\/bjo.2006.098582","article-title":"Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial","volume":"102","author":"Good","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"key":"B12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1051\/medsci\/2020163","article-title":"R\u00e9tinopathie du pr\u00e9matur\u00e9: de la pr\u00e9vention au traitement [retinopathy of prematurity: from prevention to treatment]","volume":"36","author":"Daruich","year":"2020","journal-title":"Med Sci (Paris)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1136\/bjo.79.7.637","article-title":"Diode laser treatment for retinopathy of prematurity: structural and functional outcome","volume":"79","author":"Ling","year":"1995","journal-title":"Br J Ophthalmol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3928\/01913913-20081101-02","article-title":"Structural sequelae and refractive outcome after successful laser treatment for threshold retinopathy of prematurity","volume":"45","author":"Dhawan","year":"2008","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"B16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2147\/EB.S99306","article-title":"Review of effects of anti-VEGF treatment on refractive error","volume":"8","author":"Mintz-Hittner","year":"2016","journal-title":"Eye Brain"},{"key":"B17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12886-018-0685-6","article-title":"Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in type-1 and threshold retinopathy of prematurity (ROP)","volume":"18","author":"Li","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"10.e1","DOI":"10.1016\/j.jaapos.2022.11.020","article-title":"Ocular and developmental outcomes of a dosing study of bevacizumab for retinopathy of prematurity","volume":"27","author":"Wallace","year":"2023","journal-title":"J AAPOS"},{"key":"B19","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/S2352-4642(21)00195-4","article-title":"2-year Outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial","volume":"5","author":"Marlow","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"B20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ophtha.2022.11.012","article-title":"Comparison in retreatments between bevacizumab and ranibizumab intravitreal injections for retinopathy of prematurity: a multicenter study","volume":"130","author":"Patel","year":"2023","journal-title":"Ophthalmology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1055813","DOI":"10.3389\/fped.2023.1055813","article-title":"Retinopathy of prematurity and neurodevelopmental outcomes in preterm infants: a systematic review and meta-analysis","volume":"11","author":"Diggikar","year":"2023","journal-title":"Front Pediatr"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0174964","DOI":"10.1371\/journal.pone.0174964","article-title":"Integrated network analysis reveals potentially novel molecular mechanisms and therapeutic targets of refractory epilepsies","volume":"12","author":"Chu","year":"2017","journal-title":"PLoS ONE"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s10072-012-1198-3","article-title":"Bioinformatics analysis reveals potential candidate drugs for different subtypes of glioma","volume":"34","author":"Chen","year":"2012","journal-title":"Neurol. Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1111\/resp.13401","article-title":"Insights into respiratory disease through bioinformatics","volume":"23","author":"Hurgobin","year":"2018","journal-title":"Respirology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e00713","DOI":"10.1002\/mgg3.713","article-title":"Identification of novel biomarkers and small molecule drugs in human colorectal cancer by microarray and bioinformatics analysis","volume":"7","author":"Chen","year":"2019","journal-title":"Mol. Genet. Genom. Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4626","DOI":"10.1093\/bioinformatics\/btaa563","article-title":"Screening novel drug candidates for Alzheimer\u2019s disease by an integrated network and transcriptome analysis","volume":"36","author":"Peng","year":"2020","journal-title":"Bioinformatics"},{"key":"B27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1167\/tvst.11.8.10","article-title":"Using advanced bioinformatics tools to identify novel therapeutic candidates for age-related macular degeneration","volume":"11","author":"Nadeem","year":"2022","journal-title":"Transl Vis Sci Technol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"12648","DOI":"10.3390\/ijms232012648","article-title":"Using computational drug-gene analysis to identify novel therapeutic candidates for retinal neuroprotection","volume":"23","author":"Xie","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"bav015","DOI":"10.1093\/database\/bav015","article-title":"Colorectal cancer drug target prediction using ontology-based inference and network analysis","volume":"2015","author":"Tao","year":"2015","journal-title":"Database"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1093\/bioinformatics\/bth456","article-title":"GO: termFinder\u2013open source software for accessing gene ontology information and finding significantly enriched gene ontology terms associated with a list of genes","volume":"20","author":"Boyle","year":"2004","journal-title":"Bioinformatics"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"D1007","DOI":"10.1093\/nar\/gkt1166","article-title":"Lynx: a database and knowledge extraction engine for integrative medicine","volume":"42","author":"Sulakhe","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"840030","DOI":"10.3389\/fmed.2022.840030","article-title":"Novel potential biomarkers for retinopathy of prematurity","volume":"9","author":"Tan","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.survophthal.2018.04.002","article-title":"Retinopathy of prematurity: a review of risk factors and their clinical significance","volume":"63","author":"Kim","year":"2018","journal-title":"Surv Ophthalmol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.3390\/jcm9092711","article-title":"Oxidative stress markers and the retinopathy of prematurity","volume":"9","author":"Graziosi","year":"2020","journal-title":"J Clin Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3389\/fped.2018.00369","article-title":"Oxidative stress as a primary risk factor for brain damage in preterm newborns","volume":"6","author":"Panfoli","year":"2018","journal-title":"Front Pediatr"},{"key":"B37","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jaapos.2012.12.155","article-title":"Effects of oxygen on the development and severity of retinopathy of prematurity","volume":"17","author":"Hartnett","year":"2013","journal-title":"J AAPOS"},{"key":"B38","doi-asserted-by":"publisher","first-page":"8529","DOI":"10.3390\/ijms23158529","article-title":"New aspects on the treatment of retinopathy of prematurity: currently available therapies and emerging novel therapeutics","volume":"23","author":"Ryu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.3390\/nu14112189","article-title":"Ascorbic acid and the premature infant","volume":"14","author":"Chahin","year":"2022","journal-title":"Nutrients"},{"key":"B40","doi-asserted-by":"publisher","first-page":"F117","DOI":"10.1136\/adc.2004.056440","article-title":"Vitamin C supplementation in very preterm infants: a randomised controlled trial","volume":"90","author":"Darlow","year":"2005","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"B41","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3109\/14767058.2011.629252","article-title":"Lutein and zeaxanthin supplementation in preterm infants to prevent retinopathy of prematurity: a randomized controlled study","volume":"25","author":"Dani","year":"2012","journal-title":"J Matern Fetal Neonatal Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.plefa.2008.09.015","article-title":"Effect of two doses of docosahexaenoic acid (DHA) in the diet of preterm infants on infant fatty acid status: results from the DINO trial","volume":"79","author":"Smithers","year":"2008","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.2174\/1381612824666180601094849","article-title":"The efficacy of omega-3 supplement on prevention of retinopathy of prematurity in premature infants: a randomized double-blinded controlled trial","volume":"24","author":"Khalesi","year":"2018","journal-title":"Curr Pharm Des"},{"key":"B44","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1542\/peds.79.4.489","article-title":"Tocopherol efficacy and safety for preventing retinopathy of prematurity: a randomized, controlled, double-masked trial","volume":"79","author":"Phelps","year":"1987","journal-title":"Pediatrics"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1390795","DOI":"10.1155\/2019\/1390795","article-title":"Effects of curcumin on vessel formation insight into the pro- and antiangiogenesis of curcumin","volume":"2019","author":"Wang","year":"2019","journal-title":"Evid Based Complement Alternat Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1017\/S0007114518001630","article-title":"Dietary curcumin supplementation attenuates inflammation, hepatic injury and oxidative damage in a rat model of intra-uterine growth retardation","volume":"120","author":"He","year":"2018","journal-title":"Br J Nutr"},{"key":"B47","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/sj.bjp.0703787","article-title":"N-acetylcysteine attenuates TNF-alpha-induced p38 MAP kinase activation and p38 MAP kinase-mediated IL-8 production by human pulmonary vascular endothelial cells","volume":"132","author":"Hashimoto","year":"2001","journal-title":"Br J Pharmacol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.3389\/fimmu.2017.01868","article-title":"Abnormal complement activation and inflammation in the pathogenesis of retinopathy of prematurity","volume":"8","author":"Rathi","year":"2017","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1167\/iovs.03-1303","article-title":"Genetic polymorphisms and retinopathy of prematurity","volume":"45","author":"Cooke","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B50","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4103\/jrms.JRMS_501_20","article-title":"How is insulin-like growth factor-1 correlated with retinopathy of prematurity?","volume":"26","author":"Jafari","year":"2021","journal-title":"J Res Med Sci"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/s0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (rainbow): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"12","journal-title":"Lancet"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1159\/000527470","article-title":"Comparative study of Curcumin and Lucentis on retinal neovascularization","author":"Yang","year":"2022","journal-title":"Ophthalmic Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/ptr.7350","article-title":"Curcumin supplementation in pediatric patients: a systematic review of current clinical evidence","volume":"36","author":"Heidari","year":"2022","journal-title":"Phytother Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000080089","article-title":"N-acetylcysteine administration during the first week of life does not improve lung function in extremely low birth weight infants","volume":"86","author":"Sandberg","year":"2004","journal-title":"Biol Neonate"},{"key":"B55","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jpeds.2015.09.076","article-title":"Fetal and neonatal effects of N-acetylcysteine when used for neuroprotection in maternal chorioamnionitis","volume":"168","author":"Jenkins","year":"2016","journal-title":"J Pediatr"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s00417-021-05542-0","article-title":"Role of curcumin in retinal diseases-A review","volume":"260","author":"Chandrasekaran","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1016\/j.ajpath.2011.01.036","article-title":"N-acetylcysteine amide (NACA) prevents retinal degeneration by up-regulating reduced glutathione production and reversing lipid peroxidation","volume":"178","author":"Schimel","year":"2011","journal-title":"Am J Pathol"},{"key":"B58","author":"Mehta","year":""},{"key":"B59","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1172\/JCI132990","article-title":"Oral N-acetylcysteine improves cone function in retinitis pigmentosa patients in phase I trial","volume":"130","author":"Campochiaro","year":"2020","journal-title":"J Clin Invest"},{"key":"B60","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1007\/s11033-011-1148-9","article-title":"Effect of antioxidant N-acetylcysteine on diabetic retinopathy and expression of VEGF and ICAM-1 from retinal blood vessels of diabetic rats","volume":"39","author":"Zhu","year":"2012","journal-title":"Mol Biol Rep"},{"key":"B61","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/archopht.119.5.709","article-title":"Response of experimental retinal neovascularization to thiazolidinediones","volume":"119","author":"Murata","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1167\/iovs.08-2005","article-title":"Suppression of retinal peroxisome proliferator-activated receptor gamma in experimental diabetes and oxygen-induced retinopathy: role of NADPH oxidase","volume":"50","author":"Tawfik","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B63","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/archopht.126.6.793","article-title":"Rosiglitazone and delayed onset of proliferative diabetic retinopathy","volume":"126","author":"Shen","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e0119708","DOI":"10.1371\/journal.pone.0119708","article-title":"Anti-angiogenic effect of metformin in mouse oxygen-induced retinopathy is mediated by reducing levels of the vascular endothelial growth factor receptor Flk-1","volume":"10","author":"Joe","year":"2015","journal-title":"PLoS One"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e024954","DOI":"10.1136\/bmjopen-2018-024954","article-title":"Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus","volume":"9","author":"Shi","year":"2019","journal-title":"BMJ Open"},{"key":"B66","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/ijc.32337","article-title":"Use of metformin and outcome of patients with newly diagnosed glioblastoma: pooled analysis","volume":"146","author":"Seliger","year":"2020","journal-title":"Int J Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3390\/cancers14010112","article-title":"Frontiers in anti-cancer drug discovery: challenges and perspectives of metformin as anti-angiogenic add-on therapy in glioblastoma","volume":"14","author":"Guarnaccia","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B68","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1001\/jamaophthalmol.2020.6331","article-title":"Association of metformin use with age-related macular degeneration: a case-control study","volume":"139","author":"Blitzer","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.bbrc.2012.07.165","article-title":"Metformin inhibits inflammatory response via AMPK-PTEN pathway in vascular smooth muscle cells","volume":"425","author":"Kim","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"B70","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12974-017-0943-1","article-title":"Retinopathy of prematurity: inflammation, choroidal degeneration, and novel promising therapeutic strategies","volume":"14","author":"Rivera","year":"2017","journal-title":"J Neuroinflammation"},{"key":"B71","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S2213-8587(19)30002-6","article-title":"Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial","volume":"7","author":"L\u00f8vvik","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1056\/NEJMoa0707193","article-title":"Metformin versus insulin for the treatment of gestational diabetes","volume":"358","author":"Rowan","year":"2008","journal-title":"N Engl J Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1056\/NEJMc1603067","article-title":"Metformin versus placebo in obese pregnant women without diabetes","volume":"374","author":"Stanford","year":"2016","journal-title":"N Engl J Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e000456","DOI":"10.1136\/bmjdrc-2017-000456","article-title":"Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age","volume":"6","author":"Rowan","year":"2018","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e1002848","DOI":"10.1371\/journal.pmed.1002848","article-title":"Neonatal, infant, and childhood growth following metformin versus insulin treatment for gestational diabetes: a systematic review and meta-analysis","volume":"16","author":"Tarry-Adkins","year":"2019","journal-title":"PLoS Med"},{"key":"B76","author":"Kailish","year":""},{"key":"B77","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1136\/bjo.80.2.159","article-title":"Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system","volume":"80","author":"Wagner","year":"1996","journal-title":"Br J Ophthalmol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2174\/1874364101711010122","article-title":"Many faces of renin-angiotensin system\u2014focus on eye","volume":"11","author":"Holappa","year":"2017","journal-title":"Open Ophthalmol J"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1167\/iovs.04-0885","article-title":"The renin-angiotensin system and the developing retinal vasculature","volume":"46","author":"Sarlos","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B80","doi-asserted-by":"publisher","first-page":"e0168809","DOI":"10.1371\/journal.pone.0168809","article-title":"Involvement of renin-angiotensin system in retinopathy of prematurity\u2014a possible target for therapeutic intervention","volume":"11","author":"Nath","year":"2016","journal-title":"PLoS One"},{"key":"B81","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1365-2125.1992.tb05644.x","article-title":"Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers","volume":"34","author":"Pratt","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.ophtha.2008.12.023","article-title":"Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity","volume":"116","author":"Sato","year":"2009","journal-title":"Ophthalmology"},{"key":"B83","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00246-013-0813-2","article-title":"Angiotensin-converting enzyme inhibitor nephrotoxicity in neonates with cardiac disease","volume":"35","author":"Lindle","year":"2014","journal-title":"Pediatr Cardiol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00246-016-1496-2","article-title":"Safety of enalapril in infants admitted to the neonatal intensive care unit","volume":"38","author":"Ku","year":"2017","journal-title":"Pediatr Cardiol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1161\/01.CIR.0000080735.93327.00","article-title":"Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy","volume":"108","author":"Sennlaub","year":"2003","journal-title":"Circulation"},{"key":"B86","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1167\/iovs.02-0392","article-title":"COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity","volume":"44","author":"Wilkinson-Berka","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B87","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1471-2431-4-15","article-title":"Treatment of retinopathy of prematurity with topical ketorolac tromethamine: a preliminary study","volume":"4","author":"Avila-Vazquez","year":"2004","journal-title":"BMC Pediatr"},{"key":"B88","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/pr.2016.105","article-title":"Pharmacologic synergism of ocular ketorolac and systemic caffeine citrate in rat oxygen-induced retinopathy","volume":"80","author":"Aranda","year":"2016","journal-title":"Pediatr Res"},{"key":"B89","doi-asserted-by":"publisher","first-page":"272.e1","DOI":"10.1016\/j.jaapos.2021.04.011","article-title":"The effect of ibuprofen and caffeine prophylaxis on retinopathy of prematurity","volume":"25","author":"Bhatt-Mehta","year":"2021","journal-title":"J. AAPOS"},{"key":"B90","doi-asserted-by":"publisher","first-page":"884722","DOI":"10.3389\/fgene.2022.884722","article-title":"Spectrum of mutations in NDP resulting in ocular disease; a systematic review","volume":"13","author":"Wawrzynski","year":"2022","journal-title":"Front. Genet"},{"key":"B91","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/ng1093-180","article-title":"A mutation in the Norrie disease gene (NDP) associated with X-linked familial exudative vitreoretinopathy","volume":"5","author":"Chen","year":"1993","journal-title":"Nat Genet"},{"key":"B92","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/ng957","article-title":"Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy","volume":"32","author":"Robitaille","year":"2002","journal-title":"Nat Genet"},{"key":"B93","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ajhg.2009.12.016","article-title":"Next-generation sequencing of a 40 Mb linkage interval reveals TSPAN12 mutations in patients with familial exudative vitreoretinopathy","volume":"86","author":"Nikopoulos","year":"2010","journal-title":"Am J Human Genet"},{"key":"B94","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1086\/425080","article-title":"Autosomal recessive familial exudative vitreoretinopathy is associated with mutations in LRP5","volume":"75","author":"Jiao","year":"2004","journal-title":"Am J Human Genet"},{"key":"B95","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/EB.S94452","article-title":"Wnt signaling pathway in retinal vascularization","volume":"8","author":"Drenser","year":"2016","journal-title":"Eye Brain"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1151239\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T07:12:30Z","timestamp":1688973150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1151239\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,10]]},"references-count":95,"alternative-id":["10.3389\/fped.2023.1151239"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1151239","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,10]]},"article-number":"1151239"}}